Skip to search boxSkip to navigationSkip to main content

Smoking and therapeutic response to clozapine in patients with schizophrenia

*Corresponding author for this work
  • Duke University
    ,
  • Robert Wood Johnson University Hospital
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

Background: Of patients with schizophrenia, 70 to 80% smoke. Nicotine corrects certain information processing and cognitive psychomotor deficits seen in many patients with schizophrenia. Clozapine, but not conventional antipsychotics, has been shown to correct some of these deficits. Methods: We assessed psychopathology and smoking in 70 patients with treatment refractory schizophrenia (55 smokers and 15 nonsmokers) at baseline when they were receiving conventional antipsychotics and again after they were switched to clozapine. Results: Smokers showed significantly greater therapeutic response to clozapine than nonsmokers. Smokers smoked less when treated with clozapine than when treated with conventional antipsychotics. Conclusions: Certain patients with schizophrenia have contributing pathophysiologic mechanisms that respond favorably to either nicotine or clozapine. Copyright (C) 1999 Society of Biological Psychiatry.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 125-129 (5 pages)

Journal (Volume, Issue Number)

Biological Psychiatry (Volume 46, Issue 1)

Publication milestones

  • Published - 07/1999

Publication status

Published - 07/1999

ISSN

0006-3223

Publication IDs

  • Scopus: 0033027553
  • PubMed: 10394482

Publication metrics

Metrics

Fractional count
1
Fractional count
0.33
Fractional count
2
Fractional count
0.67
Fractional count
1
Fractional count
1
SciVal
citations
162
Scopus
citations
SciVal
FWCI
2.99
SciVal
Author count
3
SciVal
Paper percentile
97
SciVal
Top percentile
5

PlumX, opens in new tab

Captures
55
Citation count
183

Funding Details

Financial support: NIDA 08434, NARSAD Independent Investigator Award (JPM).
FundersFunding numbers
NIDA 08434
08434
NIDA
R01DA008434
JPMorgan Chase and Company
-
National Alliance for Research on Schizophrenia and Depression
-